Docetaxel in combination with doxorubicin or vinorelbine

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 7, 1997, Pages

  Dieras V ^a   Fumoleau, P ^b   Kalla, S ^a   Misset, J L ^c   Azli, N ^d   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d SANOFI   (France)

Author keywords

Anthracyclines; Docetaxel; Doxorubicin; Drug combination; Metastatic breast cancer; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; NAVELBINE; TAXANE DERIVATIVE; VINCA ALKALOID;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; FEVER; HUMAN; INFECTION; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0031446832     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)90005-8     Document Type: Conference Paper

References (14)

1. van Oosterom AT, Schrijvers D. Docetaxel, (Taxotere®), a review of preclinical and clinical experience. Part II clinical experience. Anticancer Drugs 1995, 6, 356-368.
2. Ravdin P, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995, 13, 2879-2885.
3. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, 13, 2886-2894.
4. Henderson IC, Allegra JC, Woodcock T, et al. Randomized trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989, 7, 560-571.
5. Bissery MC, Nohyneck G, Sanderink GH, et al. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995, 6, 339-368.
6. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (Taxotere®): efficacy as a single agent and in combination. Semin Oncol 1995, 22 (Suppl. 13), 3-16.
7. Diéras V, Gruia G, Pouillart P, et al. A phase I study of the combination of docetaxel and doxorubicin in first line chemotherapy treatment of metastatic breast cancer: preliminary results. Breast Cancer Res 1996, 37 (Suppl. 37), abstract 313.
8. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995, 13, 2688-2699.
9. Gehl J, Bocsgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996, 7, 687-693.
10. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 1993, 11, 1245-1252.
11. Weber BL, Vogel C, Jones S, et al. A United States multicenter phase II trial of Navelbine® in advanced breast cancer. J Clin Oncol 1995, 13, 2722-2730.
12. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine® on tubulin and associated proteins. Semin Oncol 1989, 16 (Suppl. 4), 9-14.
13. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981, 91, 479-487.
14. Fumoleau P, Delecroix V, Perrocheau G, et al. Docetaxel in combination with vinorelbine as first line chemotherapy in patients with metastatic breast cancer. Preliminary results on 22 entered patients. Breast Cancer Res 1996, 37 (Suppl.), 314.